Back

The Future of HIV: Challenges in meeting the 2030 Ending the HIV Epidemic in the U.S. (EHE) reduction goal.

Bleichrodt, A.; Okano, J.; Fung, I. C.-H.; Chowell, G.; Blower, S.

2025-01-06 epidemiology
10.1101/2025.01.06.25320033 medRxiv
Show abstract

Objective(s)To predict the burden of HIV in the United States (US) nationally and by region, transmission type, and race/ethnicity through 2030. MethodsUsing publicly available data from the CDC NCHHSTP AtlasPlus dashboard, we generated 11-year prospective forecasts of incident HIV diagnoses nationally and by region (South, non-South), race/ethnicity (White, Hispanic/Latino, Black/African American), and transmission type (Injection-Drug Use, Male-to-Male Sexual Contact (MMSC), and Heterosexual Contact (HSC)). We employed weighted (W) and unweighted (UW) n-sub-epidemic ensemble models, calibrated using 12 years of historical data (2008-2019), and forecasted trends for 2020-2030. We compared results to identify persistent, concerning trends across models. ResultsWe projected substantial decreases in incident HIV diagnoses nationally (W: 27.9%, UW: 21.9%), and in the South (W:18.0%, UW: 9.2%) and non-South (W: 21.2%, UW: 19.5%) from 2019 to 2030. However, concerning non-decreasing trends were observed nationally in key sub-populations during this period: Hispanic/Latino persons (W: 1.4%, UW: 2.6%), Hispanic/Latino MMSC (W: 9.0%, UW: 9.9%), people who inject drugs (PWID) (W: 25.6%, UW: 9.2%), and White PWID (W: 3.5%, UW: 44.9%). The rising trends among Hispanic/Latino MMSC and overall PWID were consistent across the South and non-South regions. ConclusionsAlthough the forecasted national-level decrease in the number of incident HIV diagnoses is encouraging, the US is unlikely to achieve the Ending the HIV Epidemic in the U.S. goal of a 90% reduction in HIV incidence by 2030. Additionally, the observed increases among specific subpopulations highlight the importance of a targeted and equitable approach to effectively combat HIV in the US.

Matching journals

The top 2 journals account for 50% of the predicted probability mass.

1
JAIDS Journal of Acquired Immune Deficiency Syndromes
19 papers in training set
Top 0.1%
40.8%
2
PLOS ONE
4510 papers in training set
Top 15%
12.8%
50% of probability mass above
3
AIDS
31 papers in training set
Top 0.1%
5.0%
4
Clinical Infectious Diseases
231 papers in training set
Top 1%
4.5%
5
JMIR Public Health and Surveillance
45 papers in training set
Top 0.3%
4.5%
6
American Journal of Epidemiology
57 papers in training set
Top 0.3%
3.7%
7
PLOS Medicine
98 papers in training set
Top 2%
2.1%
8
American Journal of Preventive Medicine
11 papers in training set
Top 0.2%
2.0%
9
BMC Infectious Diseases
118 papers in training set
Top 2%
1.8%
10
The Journal of Infectious Diseases
182 papers in training set
Top 2%
1.7%
11
Journal of the International AIDS Society
20 papers in training set
Top 0.3%
1.3%
12
PLOS Global Public Health
293 papers in training set
Top 4%
1.3%
13
International Journal of Drug Policy
11 papers in training set
Top 0.2%
1.1%
14
Epidemiology
26 papers in training set
Top 0.4%
1.1%
15
Open Forum Infectious Diseases
134 papers in training set
Top 2%
1.0%
16
Frontiers in Public Health
140 papers in training set
Top 7%
0.8%
17
Annals of Internal Medicine
27 papers in training set
Top 0.9%
0.8%
18
AIDS and Behavior
14 papers in training set
Top 0.3%
0.8%
19
Annals of Epidemiology
19 papers in training set
Top 0.6%
0.7%
20
Emerging Infectious Diseases
103 papers in training set
Top 3%
0.7%
21
BMJ Global Health
98 papers in training set
Top 3%
0.5%
22
JAMA Network Open
127 papers in training set
Top 5%
0.5%
23
BMC Public Health
147 papers in training set
Top 7%
0.5%
24
BMJ Open
554 papers in training set
Top 14%
0.5%
25
Medical Decision Making
10 papers in training set
Top 0.4%
0.5%
26
International Journal of Environmental Research and Public Health
124 papers in training set
Top 8%
0.5%